TGA approves Aussie condom with built in anti-viral lubricant
LAST UPDATED // Tuesday, 29 July 2014 11:28 Written by // Andrew Shaw
A innovative Australian condom that carries an antiviral compound has been approved for sale in Australia.
The VivaGel condom, developed by Australian bio-tech firm Starpharma, was approved by the Australian Therapeutic Goods Administration (TGA) and will be marketed under the Ansell brand LifeStyles Dual Protect in the coming months.
The condom is a world-first product based on Australian technology, the only condom of its type, providing barrier protection and incorporating a proprietary anti-viral compound in the lubricant.
Ansell’s Peter Carroll said the first product is expected to be available on shelves soon.
“Our partnership with Starpharma is a great example of two highly innovative Australian businesses working together to bring to market a ground-breaking new sexual health product. New product development is central to Ansell’s business strategy and this highly innovative product is exciting for both companies.”
The condoms are lubricated with VivaGel, which contains 0.5 per cent astodrimer sodium. Starpharma says the product is intended to help reduce the risk of exposure to viruses that cause STIs, having been shown in laboratory studies to inactivate up to 99.9 per cent of HIV, HSV (herpes simplex virus) and HPV (human papillomavirus).
Starpharma has a licensing agreement that provides marketing rights to Ansell for the VivaGel condom in countries outside of Japan.
In Japan, Starpharma has licensed the product to Okamoto Industries, Japan’s leading marketer of condoms with approximately 60 per cent of the Japanese condom market, the second largest global market next to the US.